Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode
Open Access
- 18 November 2022
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Abstract
The TEA domain (TEAD) transcription factor forms a transcription co-activation complex with the key downstream effector of the Hippo pathway, YAP/TAZ. TEAD-YAP controls the expression of Hippo-responsive genes involved in cell proliferation, development, and tumorigenesis. Hyperactivation of TEAD-YAP activities is observed in many human cancers and is associated with cancer cell proliferation, survival, and immune evasion. Therefore, targeting the TEAD-YAP complex has emerged as an attractive therapeutic approach. We previously reported that the mammalian TEAD transcription factors (TEAD1–4) possess auto-palmitoylation activities and contain an evolutionarily conserved palmitate-binding pocket (PBP), which allows small-molecule modulation. Since then, several reversible and irreversible inhibitors have been reported by binding to PBP. Here, we report a new class of TEAD inhibitors with a novel binding mode. Representative analog TM2 shows potent inhibition of TEAD auto-palmitoylation both in vitro and in cells. Surprisingly, the co-crystal structure of the human TEAD2 YAP-binding domain (YBD) in complex with TM2 reveals that TM2 adopts an unexpected binding mode by occupying not only the hydrophobic PBP, but also a new side binding pocket formed by hydrophilic residues. RNA-seq analysis shows that TM2 potently and specifically suppresses TEAD-YAP transcriptional activities. Consistently, TM2 exhibits strong antiproliferation effects as a single agent or in combination with a MEK inhibitor in YAP-dependent cancer cells. These findings establish TM2 as a promising small-molecule inhibitor against TEAD-YAP activities and provide new insights for designing novel TEAD inhibitors with enhanced selectivity and potency.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01CA219814)
- National Cancer Institute (R01CA238270)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK127180)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK127207)
- Welch Foundation (I-1932)
- Antidote Health Foundation for the cure of cancer (postdoc fellowship)
This publication has 49 references indexed in Scilit:
- LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascadeOncogene, 2013
- LATS2 Is a Tumor Suppressor Gene of Malignant MesotheliomaCancer Research, 2011
- The Hippo Signaling Pathway in Development and CancerDevelopmental Cell, 2010
- Lipophilicity in drug discoveryExpert Opinion on Drug Discovery, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- TEAD mediates YAP-dependent gene induction and growth controlGenes & Development, 2008
- The TEAD/TEF Family Protein Scalloped Mediates Transcriptional Output of the Hippo Growth-Regulatory PathwayDevelopmental Cell, 2008
- Hippo signaling in organ size controlGenes & Development, 2007
- Announcing the worldwide Protein Data BankNature Structural & Molecular Biology, 2003
- [20] Processing of X-ray diffraction data collected in oscillation mode1997